Study design and patients
viral retinitis, keratopathy, retinal atrophy, opacity, hypotony, SO tamponade, cataract, PD, retinal redetachment, glaucoma
DIABETIC RETINOPATHY, CHRONIC UVEITIS, KERATOPATHY, RETINAL ATROPHY, OPACITY, RETINAL TEAR, RETINA, CATARACT, MAY, SECONDARY, HIGH MYOPIA, LENS, RETINAL DETACHMENT, GLAUCOMA, GIANT, MACULAR EDEMA, EYE
This single-center case series prospectively included consecutive patients who underwent SO removal from June to December 2019 at Chongqing Aier Eye Hospital. Patients who underwent SO removal combined with phacoemulsification and intraocular lens implantation were included. The inclusion criteria were (1) intravitreal SO tamponade in one eye for primary macula-off rhegmatogenous retinal detachment and normal macular morphology of the attached retina, (2) PVR grade A or B, (3) macular involvement, (4) hole size < 2 PD, (5) best-corrected visual acuity (BCVA) in the eye administered SO tamponade > 0.1 using the international standard visual acuity chart, (6) no SO emulsification, (7) clear media in both eyes, (8) without hypotony, (9) without viral retinitis, and (10) without chronic uveitis. The exclusion criteria were: (1) keratopathy, severe cataract, or diabetic retinopathy, (2) macular edema or hole, (3) giant retinal tear, (4) high myopia or retinal atrophy caused by high myopia, (5) glaucoma, (6) secondary epiretinal membrane (ERM), (7) retinal redetachment during follow-up, (8) optical media opacity overtly interfering with OCT imaging, or (9) pediatric retinal detachment. Patients with suspected drug toxic side effects were not excluded because the causality could not be determined with certainty. Eyes with SO tamponade that met the above criteria were selected as the SO tamponade eye group. Contralateral eyes with BCVA (LogMAR) < 0.1 and OCTA signal strength above 8 were selected as control eyes.When the current study was first designed, there was no perfluoropropane (CThe study was performed according to the Declaration of Helsinki. It was approved by the Ethics Committee of Chongqing Aier Eye Hospital (EC approval number: IRB2019009). All participants provided signed informed consent. Clinical trial registration: Registration date: May 22, 2019; Registration number, ChiCTR1900023322; Registration site, Chinese Clinical Trial Registry (ChiCTR).